{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:07:05Z","timestamp":1784704025944,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To summarize the developing evidence on novel 2-benzlbenzimidazole opioids (nitazene analogs), including pharmacology, potency, toxicology, management of overdose, and public health issues that are caused by this set of compounds as there is an increasing presence in illicit drug markets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Nitazene analogs include those such as isotonitazene, metonitazene, protonitazene, and etonitazene are highly potent mu opioid receptor agonists and are increasingly detected in counterfeit and illicit pharmaceutical products with exposure in other substances including other drugs. Reports from multiple clinical, forensic, and public health investigations have all demonstrated that severe opioid toxicity can be characterized by profound respiratory depression, which is seen in nitazene compounds. Detection remains a central issue with this compound because these derivatives frequently are missed in routine toxicology screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Nitazene analogs represent a new class of synthetic opioids that are associated with a high overdose risk related to high potency and increased prevalence worldwide. New techniques for overdose reversal include improvements in the pharmacology of opioid antagonists, prolonged and improved monitoring, and advances in life support inside and outside the hospital setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11916-026-01525-0","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:27:39Z","timestamp":1784701659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs"],"prefix":"10.1007","volume":"30","author":[{"given":"Mary Kathryn","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"Pt B","key":"1525_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bpobgyn.2022.07.003","volume":"85","author":"JL Cook","year":"2022","unstructured":"Cook JL. The opioid epidemic. Best Pract Res Clin Obstet Gynaecol. 2022;85(Pt B):53\u20138. https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.07.003.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"1525_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40122-018-0097-6","volume":"7","author":"MR Jones","year":"2018","unstructured":"Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A Brief History of the Opioid Epidemic and Strategies for Pain Medicine. Pain Therapy. 2018;7(1):13\u201321. https:\/\/doi.org\/10.1007\/s40122-018-0097-6.","journal-title":"Pain Therapy"},{"key":"1525_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40736","author":"J Pergolizzi Jr","year":"2023","unstructured":"Pergolizzi J Jr, Raffa R, LeQuang JAK, Breve F, Varrassi G. Old Drugs and New Challenges: A Narrative Review of Nitazenes. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.40736.","journal-title":"Cureus"},{"issue":"4","key":"1525_CR4","first-page":"329","volume":"122","author":"ES Schwarz","year":"2025","unstructured":"Schwarz ES, Dicker F, Lothet E, Spungen H, Levine M. Nitazenes: An Old Drug Class Causing New Problems. Mo Med. 2025;122(4):329\u201333.","journal-title":"Mo Med"},{"issue":"4","key":"1525_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/PAF.0000000000000787","volume":"43","author":"DM Papsun","year":"2022","unstructured":"Papsun DM, Krotulski AJ, Logan BK. Proliferation of Novel Synthetic Opioids in Postmortem Investigations After Core-Structure Scheduling for Fentanyl-Related Substances. Am J Forensic Med Pathol. 2022;43(4):315\u201327. https:\/\/doi.org\/10.1097\/PAF.0000000000000787.","journal-title":"Am J Forensic Med Pathol"},{"issue":"2","key":"1525_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/jpet.123.002052","volume":"389","author":"LB Kozell","year":"2024","unstructured":"Kozell LB, Eshleman AJ, Wolfrum KM, Swanson TL, Bloom SH, Benware S, et al. Pharmacologic Characterization of Substituted Nitazenes at \u00b5, \u03ba, and \u2206 Opioid Receptors Suggests High Potential for Toxicity. J Pharmacol Exp Ther. 2024;389(2):219\u201328. https:\/\/doi.org\/10.1124\/jpet.123.002052.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1525_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/FTD.0000000000000970","volume":"44","author":"E Montanari","year":"2022","unstructured":"Montanari E, Madeo G, Pichini S, Busard\u00f2 FP, Carlier J. Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review. Ther Drug Monit. 2022;44(4):494\u2013510. https:\/\/doi.org\/10.1097\/FTD.0000000000000970.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"1525_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/jat\/bkaf046","volume":"49","author":"AL Pacana","year":"2025","unstructured":"Pacana AL, Skillman BN. A novel screening workflow for nitazene analogs using LC-MS\/MS precursor ion scan acquisition. J Anal Toxicol. 2025;49(8):520\u20138. https:\/\/doi.org\/10.1093\/jat\/bkaf046.","journal-title":"J Anal Toxicol"},{"issue":"7","key":"1525_CR9","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s00204-024-03735-0","volume":"98","author":"O Taoussi","year":"2024","unstructured":"Taoussi O, Berardinelli D, Zaami S, Tavoletta F, Basile G, Kronstrand R, et al. Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene. Arch Toxicol. 2024;98(7):2101\u201316. https:\/\/doi.org\/10.1007\/s00204-024-03735-0.","journal-title":"Arch Toxicol"},{"issue":"4","key":"1525_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/dta.2738","volume":"12","author":"P Blanckaert","year":"2020","unstructured":"Blanckaert P, Cannaert A, Van Uytfanghe K, Hulpia F, Deconinck E, Van Calenbergh S, et al. Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. Drug Test Anal. 2020;12(4):422\u201330. https:\/\/doi.org\/10.1002\/dta.2738.","journal-title":"Drug Test Anal"},{"issue":"4","key":"1525_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/dta.3415","volume":"15","author":"T Kanamori","year":"2023","unstructured":"Kanamori T, Okada Y, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, et al. Analysis of highly potent synthetic opioid nitazene analogs and their positional isomers. Drug Test Anal. 2023;15(4):449\u201357. https:\/\/doi.org\/10.1002\/dta.3415.","journal-title":"Drug Test Anal"},{"issue":"12","key":"1525_CR12","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00213-023-06451-2","volume":"240","author":"GC Glatfelter","year":"2023","unstructured":"Glatfelter GC, Vandeputte MM, Chen L, Walther D, Tsai MHM, Shi L, et al. Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u2018nitazene\u2019 opioids associated with human overdose. Psychopharmacology. 2023;240(12):2573\u201384. https:\/\/doi.org\/10.1007\/s00213-023-06451-2.","journal-title":"Psychopharmacology"},{"issue":"9","key":"1525_CR13","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s00204-024-03774-7","volume":"98","author":"LM De Vrieze","year":"2024","unstructured":"De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, et al. In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole \u2018nitazene\u2019 opioids. Arch Toxicol. 2024;98(9):2999\u20133018. https:\/\/doi.org\/10.1007\/s00204-024-03774-7.","journal-title":"Arch Toxicol"},{"issue":"3","key":"1525_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jat\/bkab117","volume":"46","author":"SE Walton","year":"2022","unstructured":"Walton SE, Krotulski AJ, Logan BK. A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography-Tandem Quadrupole Mass Spectrometry (LC-QQQ-MS). J Anal Toxicol. 2022;46(3):221\u201331. https:\/\/doi.org\/10.1093\/jat\/bkab117.","journal-title":"J Anal Toxicol"},{"issue":"10","key":"1525_CR15","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/dta.3115","volume":"13","author":"AJ Krotulski","year":"2021","unstructured":"Krotulski AJ, Papsun DM, Walton SE, Logan BK. Metonitazene in the United States-Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry. Drug Test Anal. 2021;13(10):1697\u2013711. https:\/\/doi.org\/10.1002\/dta.3115.","journal-title":"Drug Test Anal"},{"key":"1525_CR16","doi-asserted-by":"publisher","unstructured":"Nguyen A, Donnelly J, Robinson CL, Hasoon J. Commonly used opioids in the orthopedic operating room: A narrative review. Orthop Rev. 18: 158576. https:\/\/doi.org\/10.52965\/001c.158576.","DOI":"10.52965\/001c.158576"},{"key":"1525_CR17","doi-asserted-by":"publisher","first-page":"107503","DOI":"10.1016\/j.phrs.2024.107503","volume":"210","author":"MM Vandeputte","year":"2024","unstructured":"Vandeputte MM, Glatfelter GC, Walther D, Layle NK, St Germaine DM, Ujv\u00e1ry I, et al. Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro \u00b5-opioid receptor assays and in vivo behavioral studies in mice. Pharmacol Res. 2024;210:107503. https:\/\/doi.org\/10.1016\/j.phrs.2024.107503.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1525_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/15563650.2025.2504133","volume":"63","author":"M Stangeland","year":"2025","unstructured":"Stangeland M, Dale O, Skulberg AK. Nitazenes: review of comparative pharmacology and antagonist action. Clin Toxicol. 2025;63(6):393\u2013406. https:\/\/doi.org\/10.1080\/15563650.2025.2504133.","journal-title":"Clin Toxicol"},{"issue":"2","key":"1525_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00204-025-04163-4","volume":"100","author":"D Berardinelli","year":"2026","unstructured":"Berardinelli D, Taoussi O, Ovat DY, Pichini S, Pulver B, Auw\u00e4rter V, et al. Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on \u00b5-opioid receptor docking simulations. Arch Toxicol. 2026;100(2):543\u201356. https:\/\/doi.org\/10.1007\/s00204-025-04163-4.","journal-title":"Arch Toxicol"},{"issue":"2","key":"1525_CR20","doi-asserted-by":"publisher","first-page":"e70078","DOI":"10.1111\/bcpt.70078","volume":"137","author":"J Verbeek","year":"2025","unstructured":"Verbeek J, Brinkman DJ. A Comprehensive Narrative Review of Protonitazene: Pharmacological Characteristics, Detection Techniques, and Toxicology. Basic Clin Pharmacol Toxicol. 2025;137(2):e70078. https:\/\/doi.org\/10.1111\/bcpt.70078.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1525_CR21","doi-asserted-by":"publisher","first-page":"110470","DOI":"10.1016\/j.neuropharm.2025.110470","volume":"275","author":"MM Vandeputte","year":"2025","unstructured":"Vandeputte MM, Stove CP. Navigating nitazenes: A pharmacological and toxicological overview of new synthetic opioids with a 2-benzylbenzimidazole core. Neuropharmacology. 2025;275:110470. https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110470.","journal-title":"Neuropharmacology"},{"key":"1525_CR22","doi-asserted-by":"publisher","first-page":"110686","DOI":"10.1016\/j.forsciint.2021.110686","volume":"320","author":"F Mueller","year":"2021","unstructured":"Mueller F, Bogdal C, Pfeiffer B, Andrello L, Ceschi A, Thomas A, et al. Isotonitazene: Fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland. Forensic Sci Int. 2021;320:110686. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110686.","journal-title":"Forensic Sci Int"},{"issue":"19","key":"1525_CR23","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/molecules30193890","volume":"30","author":"JRP Pereira","year":"2025","unstructured":"Pereira JRP, Quintas A, Neng NR, Nitazenes. The Emergence of a Potent Synthetic Opioid Threat. Molecules. 2025;30(19):3890. https:\/\/doi.org\/10.3390\/molecules30193890.","journal-title":"Molecules"},{"issue":"3","key":"1525_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bpa.2020.06.003","volume":"34","author":"K Gress","year":"2020","unstructured":"Gress K, Charipova K, Jung JW, Kaye AD, Paladini A, Varrassi G, et al. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):449\u201361. https:\/\/doi.org\/10.1016\/j.bpa.2020.06.003.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"4","key":"1525_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bph.17376","volume":"182","author":"N Alhosan","year":"2025","unstructured":"Alhosan N, Cavallo D, Santiago M, Kelly E, Henderson G. Slow dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal at the \u00b5-opioid receptor. Br J Pharmacol. 2025;182(4):969\u201387. https:\/\/doi.org\/10.1111\/bph.17376.","journal-title":"Br J Pharmacol"},{"issue":"37","key":"1525_CR26","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.15585\/mmwr.mm7137a5","volume":"71","author":"A Roberts","year":"2022","unstructured":"Roberts A, Korona-Bailey J, Mukhopadhyay S. Notes from the Field: Nitazene-Related Deaths \u2014 Tennessee, 2019\u20132021. MMWR Morb Mortal Wkly Rep. 2022;71(37):1196\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7137a5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1525_CR27","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1111\/dar.70040","volume":"45","author":"S Nielsen","year":"2026","unstructured":"Nielsen S, Silva JP, Jones JD, Krotulski A, Poovendran D, Muzangizi D, et al. Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids. Drug Alcohol Rev. 2026;45(1):e70040. https:\/\/doi.org\/10.1111\/dar.70040.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"1525_CR28","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2468-2667(24)00001-X","volume":"9","author":"A Holland","year":"2024","unstructured":"Holland A, Copeland CS, Shorter GW, Connolly DJ, Wiseman A, Mooney J, et al. Nitazenes-heralding a second wave for the UK drug-related death crisis? Lancet Public Health. 2024;9(2):e71\u20132. https:\/\/doi.org\/10.1016\/S2468-2667(24)00001-X.","journal-title":"Lancet Public Health"},{"issue":"5","key":"1525_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.annemergmed.2025.06.619","volume":"86","author":"DM Roberts","year":"2025","unstructured":"Roberts DM, Tisdell B, Sajeev MF, Jiranantakan T, Harvey C, Brown JA. Clinical Experiences With the Nitazene Class of Synthetic Opioids: A Cohort Study. Ann Emerg Med. 2025;86(5):475\u201383. https:\/\/doi.org\/10.1016\/j.annemergmed.2025.06.619.","journal-title":"Ann Emerg Med"},{"issue":"6","key":"1525_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/metabo15060371","volume":"15","author":"R Magny","year":"2025","unstructured":"Magny R, Schiestel T, M\u2019Rad A, Lefr\u00e8re B, Raphalen JH, Ledochowski S, et al. Comparison of the Metabolic Profiles Associated with Protonitazene and Protonitazepyne in Two Severe Poisonings. Metabolites. 2025;15(6):371. https:\/\/doi.org\/10.3390\/metabo15060371.","journal-title":"Metabolites"},{"issue":"8","key":"1525_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/15563650.2024.2383692","volume":"62","author":"R Syrjanen","year":"2024","unstructured":"Syrjanen R, Schumann JL, Castle JW, Sharp L, Griffiths A, Blakey K, et al. Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in Australia. Clin Toxicol. 2024;62(8):539\u201341. https:\/\/doi.org\/10.1080\/15563650.2024.2383692.","journal-title":"Clin Toxicol"},{"issue":"9","key":"1525_CR32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/15563650.2022.2084406","volume":"60","author":"DP Calello","year":"2022","unstructured":"Calello DP, Aldy K, Jefri M, Nguyen TAT, Krotulski A, Logan B, et al. Identification of a novel opioid, N -piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol. 2022;60(9):1067\u20139. https:\/\/doi.org\/10.1080\/15563650.2022.2084406.","journal-title":"Clin Toxicol"},{"key":"1525_CR33","doi-asserted-by":"publisher","first-page":"109263","DOI":"10.1016\/j.neuropharm.2022.109263","volume":"221","author":"MA De Luca","year":"2022","unstructured":"De Luca MA, Tocco G, Mostallino R, Laus A, Caria F, Musa A, et al. Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent \u00b5-opioid receptor agonists. Neuropharmacology. 2022;221:109263. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109263.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1525_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5694\/mja2.52605","volume":"222","author":"B Clifford","year":"2025","unstructured":"Clifford B, Peacock A, Siefried KJ, Gobeil J, Smith JL, Ezard N. Responding to reports of nitazene toxicity in Australia. Med J Aust. 2025;222(5):216\u20139. https:\/\/doi.org\/10.5694\/mja2.52605.","journal-title":"Med J Aust"},{"issue":"8","key":"1525_CR35","doi-asserted-by":"publisher","first-page":"e2331264","DOI":"10.1001\/jamanetworkopen.2023.31264","volume":"6","author":"A Amaducci","year":"2023","unstructured":"Amaducci A, Aldy K, Campleman SL, Li S, Meyn A, Abston S, et al. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Netw Open. 2023;6(8):e2331264. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31264.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1525_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40262-024-01355-6","volume":"63","author":"TI Saari","year":"2024","unstructured":"Saari TI, Strang J, Dale O. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clin Pharmacokinet. 2024;63(4):397\u2013422. https:\/\/doi.org\/10.1007\/s40262-024-01355-6.","journal-title":"Clin Pharmacokinet"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"1346109","DOI":"10.3389\/fpubh.2024.1346109","volume":"12","author":"A Dahan","year":"2024","unstructured":"Dahan A, Franko TS, Carroll JW, Craig DS, Crow C, Galinkin JL, et al. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front Public Health. 2024;12:1346109. https:\/\/doi.org\/10.3389\/fpubh.2024.1346109.","journal-title":"Front Public Health"},{"key":"1525_CR38","doi-asserted-by":"publisher","first-page":"104323","DOI":"10.1016\/j.drugpo.2024.104323","volume":"124","author":"AF Infante","year":"2024","unstructured":"Infante AF, Elmes AT, Gimbar RP, Messmer SE, Neeb C, Jarrett JB. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement. Int J Drug Policy. 2024;124:104323. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104323.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1525_CR39","doi-asserted-by":"publisher","first-page":"35318","DOI":"10.52965\/001c.35318","volume":"14","author":"K Berardino","year":"2022","unstructured":"Berardino K, Carroll AH, Popovsky D, Ricotti R, Civilette MD, Sherman WF, et al. Opioid Use Consequences, Governmental Strategies, and Alternative Pain Control Techniques Following Total Hip Arthroplasties. Orthop Rev. 2022;14(4):35318. https:\/\/doi.org\/10.52965\/001c.35318.","journal-title":"Orthop Rev"},{"issue":"3","key":"1525_CR40","doi-asserted-by":"publisher","first-page":"37496","DOI":"10.52965\/001c.37496","volume":"14","author":"K Berardino","year":"2022","unstructured":"Berardino K, Carroll AH, Ricotti R, Popovsky D, Civilette MD, Urits I, et al. The Ramifications of Opioid Utilization and Outcomes of Alternative Pain Control Strategies for Total Knee Arthroplasties. Orthop Rev. 2022;14(3):37496. https:\/\/doi.org\/10.52965\/001c.37496.","journal-title":"Orthop Rev"},{"issue":"1","key":"1525_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12954-025-01287-9","volume":"22","author":"V Marland","year":"2025","unstructured":"Marland V, Nisbet L, Nic Da\u00e9id N. Evaluation of nitazene immunoassay test strips for rapid in-situ detection of nitazene and nitazene analogs in illicit drug samples. Harm Reduct J. 2025;22(1):137. https:\/\/doi.org\/10.1186\/s12954-025-01287-9.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1525_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12954-024-01078-8","volume":"21","author":"LM De Vrieze","year":"2024","unstructured":"De Vrieze LM, Stove CP, Vandeputte MM. Nitazene test strips: a laboratory evaluation. Harm Reduct J. 2024;21(1):159. https:\/\/doi.org\/10.1186\/s12954-024-01078-8.","journal-title":"Harm Reduct J"},{"key":"1525_CR43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.99109","author":"A Al-Juhani","year":"2025","unstructured":"Al-Juhani A, Alasmari A, Aljohani OO, Hakeem H, Desoky R, Badghaish MA, et al. Decoding the Unseen: A Systematic Review of the Analytical Performance of Nitazene Test Strips for Identifying Synthetic Opioids in Seized Drug Materials. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.99109.","journal-title":"Cureus"},{"issue":"1","key":"1525_CR44","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2468-2667(24)00273-1","volume":"10","author":"J Friedman","year":"2025","unstructured":"Friedman J, Ciccarone D. The public health risks of counterfeit pills. Lancet Public Health. 2025;10(1):e58\u201362. https:\/\/doi.org\/10.1016\/S2468-2667(24)00273-1.","journal-title":"Lancet Public Health"},{"key":"1525_CR45","doi-asserted-by":"publisher","first-page":"112717","DOI":"10.1016\/j.forsciint.2025.112717","volume":"378","author":"A Mayer","year":"2026","unstructured":"Mayer A, Montgomery N, Hughes E, Birks Ang B, Johnson OE. Detection and characterisation of a new nitazene analogue, butodesnitazene: A collaborative approach to the identification of novel psychoactive substances through Drug Checking. Forensic Sci Int. 2026;378:112717. https:\/\/doi.org\/10.1016\/j.forsciint.2025.112717.","journal-title":"Forensic Sci Int"},{"key":"1525_CR46","doi-asserted-by":"publisher","first-page":"88398","DOI":"10.52965\/001c.88398","volume":"15","author":"D Segina","year":"2023","unstructured":"Segina D, Ryaby J. Osteogenesis Stimulator Devices Reduce Surgical Intervention, Opioid Utilization, and Overall Costs in Patients with Fracture Nonunions. Orthop Rev. 2023;15:88398. https:\/\/doi.org\/10.52965\/001c.88398.","journal-title":"Orthop Rev"},{"issue":"9","key":"1525_CR47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/add.70027","volume":"120","author":"R Bade","year":"2025","unstructured":"Bade R, Nadarajan D, Hall W, Brown JA, Wastewater Consortium NPS, Schumann J. Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries. Addiction. 2025;120(9):1739\u201346. https:\/\/doi.org\/10.1111\/add.70027.","journal-title":"Addiction"},{"issue":"2","key":"1525_CR48","doi-asserted-by":"publisher","first-page":"24978","DOI":"10.52965\/001c.24978","volume":"13","author":"K Berardino","year":"2021","unstructured":"Berardino K, Carroll AH, Kaneb A, Civilette MD, Sherman WF, Kaye AD. An Update on Postoperative Opioid Use and Alternative Pain Control Following Spine Surgery. Orthop Rev. 2021;13(2):24978. https:\/\/doi.org\/10.52965\/001c.24978.","journal-title":"Orthop Rev"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01525-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:27:40Z","timestamp":1784701660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-026-01525-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01525-0","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"14 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"93"}}